Phase I study of recombinant beta-interferon given by four-hour infusion

Area of Science:

• Oncology
• Pharmacology
• Immunotherapy

Background:

• Advanced malignant diseases require novel therapeutic strategies.
• Interferon-based therapies are explored for their immunomodulatory and anti-cancer effects.

Purpose of the Study:

• To evaluate the safety and tolerability of escalating doses of beta-interferon serine in patients with advanced malignant disease.
• To determine a maximal starting dose and dose escalation strategy for this investigational therapy.

Main Methods:

• Phase I clinical trial involving twelve patients with advanced malignant disease.
• Administered beta-interferon serine via 4-hour intravenous infusion twice weekly.
• Dose escalation within patients allowed up to 400 MU/m2; starting doses were 0.01, 1, 10, and 30 MU/m2.

Main Results:

• Common toxicities included fever, chills, fatigue, and acral cyanosis, increasing with dose.
• A maximal starting dose of 10 MU/m2 was identified; patients starting at 30 MU/m2 could not tolerate continued therapy.
• Detectable serum interferon levels correlated with significant toxicity at 10 and 30 MU/m2.

Conclusions:

• A maximal starting dose of 10 MU/m2 for beta-interferon serine is recommended for Phase I studies.
• Gradual dose escalation, contingent on tolerance to side effects, is advised for this intravenous infusion regimen.
• Further investigation into the therapeutic window and optimal dosing of beta-interferon serine in advanced cancers is warranted.